Karyopharm Therapeutics (KPTI) Insider Trading & Ownership $4.35 -0.08 (-1.81%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.33 -0.02 (-0.55%) As of 07/25/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Karyopharm Therapeutics (NASDAQ:KPTI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.98%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$13.11K Get KPTI Insider Trade Alerts Want to know when executives and insiders are buying or selling Karyopharm Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KPTI Insider Buying and Selling by Quarter Karyopharm Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/22/2025Kristin AbateCAOSell238$4.00$952.00 4/23/2025Reshma RangwalaEVPSell419$6.17$2,585.23 10/4/2024Richard A PaulsonCEOSell240$13.20$3,168.00 8/6/2024Richard A PaulsonCEOSell240$13.95$3,348.00 7/30/2024Stuart PoultonEVPSell192$15.90$3,052.80 (Data available from 1/1/2013 forward) KPTI Insider Trading Activity - Frequently Asked Questions Who is on Karyopharm Therapeutics' Insider Roster? The list of insiders at Karyopharm Therapeutics includes Deepika Pakianathan, Garen G Bohlin, Kristin Abate, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sohanya Roshan Cheng, Stephen Mitchener, and Stuart Poulton. Learn more on insiders at KPTI. What percentage of Karyopharm Therapeutics stock is owned by insiders? 2.98% of Karyopharm Therapeutics stock is owned by insiders. Learn more on KPTI's insider holdings. Which Karyopharm Therapeutics insiders have been buying company stock? The following insider purchased KPTI shares in the last 24 months: Garen G Bohlin ($50,178.60). How much insider buying is happening at Karyopharm Therapeutics? Insiders have purchased a total of 2,742 KPTI shares in the last 24 months for a total of $50,178.60 bought. Which Karyopharm Therapeutics insiders have been selling company stock? The following insiders have sold KPTI shares in the last 24 months: Deepika Pakianathan ($1,224,177.30), Kristin Abate ($952.00), Michael Mano ($25,016.10), Michael Mason ($52,219.50), Reshma Rangwala ($28,840.03), Richard A Paulson ($147,394.50), Sohanya Roshan Cheng ($9,855.30), and Stuart Poulton ($15,632.85). How much insider selling is happening at Karyopharm Therapeutics? Insiders have sold a total of 100,463 Karyopharm Therapeutics shares in the last 24 months for a total of $1,504,087.58 sold. Karyopharm Therapeutics Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 57)President, CEO & Director Compensation: $1.43MMs. Sohanya Cheng M.B.A. (Age 41)Executive VP & Chief Commercial Officer Compensation: $742.95kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Reshma Rangwala M.D. (Age 46)Ph.D., Executive VP, Chief Medical Officer & Head of Research Compensation: $777.32kDr. Mansoor Raza Mirza M.D. (Age 63)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Compensation: $150kDr. Sharon Shacham M.B.A. (Age 54)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Compensation: $1.4MMr. Cameron Peters (Age 64)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. Michael J. Mano J.D. (Age 47)Senior VP, General Counsel & Secretary Compensation: $625.08kMr. James Accumanno J.D.Chief Compliance Officer More Insider Trading Tools from MarketBeat Related Companies MiNK Therapeutics Insider Buying Caribou Biosciences Insider Buying Lifevantage Insider Buying Immuneering Insider Buying Enanta Pharmaceuticals Insider Buying Spero Therapeutics Insider Buying Lexeo Therapeutics Insider Buying Greenwich LifeSciences Insider Buying Rapt Therapeutics Insider Buying Inhibikase Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:KPTI) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
